...

https://www.clinigengroup.com/news/news-container/2023/clinigen-divests-global-rights-to-four-cancer-support-therapies-to-cnx-therapeutics/#:~:text=Under%20the%20terms%20of%20the,treated%20with%20other%20cancer%20therapies.


CLINIGEN DIVESTS GLOBAL RIGHTS TO FOUR CANCER SUPPORT THERAPIES TO CNX THERAPEUTICS

Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients

Under the terms of the agreement, (the financial terms for which are not being disclosed), Clinigen will divest four medicines; Cardioxane®, Savene®, Totect® a nd Ethyol®, all of which help mitigate the side effects patients may experience when treated with other cancer therapies.

Cardioxane®, used in adults with advanced or metastatic breast cancer to prevent long-term harmful effects on the heart caused by treatment with certain anthracyclines.

Savene®, used to treat anthracycline extravasation in adults, a rare condition that can impact cancer patients.

Totect®, used for the treatment of anthracycline extravasation as well as for preventing cardiomyopathy associated with doxorubicin in women with metastatic breast cancer.

Ethyol®, used to reduce the cumulative renal toxicity of cisplatin in patients with advanced ovarian cancer and for reduction of the toxic effects of radiation on normal oral tissues in patients with head and neck cancer.

Dexrazoxane sale, this is a base case metric for cardio protect only. The licensing of each indication combo is interesting. Whilst financial agreement is not disclosed will can find out when reporting period kicks off in the UK for CNX Therapeutics, but seems like low value?